Join to View Full Profile
3730 S Eastern AveLas Vegas, NV 89169
Phone+1 702-952-3400
Fax+1 702-952-3461
Dr. Kingsley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Edwin Kingsley is an oncologist based in Las Vegas, NV, specializing in hematology and medical oncology. He completed his fellowship and residency at the University of Arizona College of Medicine-Tucson after graduating from the University of Utah School of Medicine. His expertise includes general and benign hematology. Dr. Kingsley has contributed to several publications, including studies on zanubrutinib and ibrutinib-intolerant patients, and he has been involved in multiple clinical trials notably as a Principal Investigator. His work has been recognized with a Top MD award from Consumers Checkbook.
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1983 - 1985- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1980 - 1983
University of Utah School of MedicineClass of 1980
Certifications & Licensure
NV State Medical License 1985 - 2027
AZ State Medical License 1981 - 2020
UT State Medical License 1985 - 1986
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- Top MD Consumers Checkbook
Clinical Trials
- Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
- A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia Start of enrollment: 2018 Nov 01
Publications & Presentations
PubMed
- Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial.Milind Javle, Christos Fountzilas, Chih-Yi Liao, Meredith Pelster, Daneng Li
The Lancet. Gastroenterology & Hepatology. 2026-02-01 - 1 citationsGenomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01 - 53 citationsROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.Pier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, Fontanet Bijou, Ana C De Oliveira
Journal of Clinical Oncology. 2023-11-20
Press Mentions
Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021- Health Care Quarterly’s 2020 Top DoctorsAugust 20th, 2020
- Top Doctors 2020August 1st, 2020
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
